National Institute of Health Highlights Importance of Ketamine as a New and Faster Path to Treating Depression

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Sunbelt Wellness Institute (https://sunbeltwellness.com) is North Florida’s premier leader in Ketamine Infusion Therapy for mood disorders and chronic pain conditions. Ketamine Infusion Therapy delivers effective results to individuals wrestling with depression, PTSD, bipolar depression, and chronic pain. The National Institute of Health has laid out strategic objectives to prioritize efforts attempting to tackle these notoriously difficult to treat diseases. Sunbelt Wellness Institute is the ONLY provider in the North Florida area with expertly trained anesthesia clinicians, delivering treatments in a safe and comfortable environment.

Several clinical studies have confirmed the potential of the glutamate pathway as a target for the development of new antidepressants. Continuing research with ketamine has provided information on biomarkers that could be used to predict who will respond to treatment.

Clinical studies are also testing analogs of Ketamine in an effort to develop glutamate inhibitors with lower side effect profiles. Ketamine may also have potential for treating other mental illnesses, including the increased anxiety found in some forms of depression and PTSD.

Investigation of the role of glutamate signaling in other illnesses may provide the impetus to develop novel therapies based on this pathway.

https://www.nimh.nih.gov/about/strategic-planning-reports/highlights/highlight-ketamine-a-new-and-faster-path-to-treating-depression.shtml
Cornwell, B. R., Salvadore, G., Furey, M., Marquardt, C. A., Brutsche, N. E., Grillon, C., & Zarate Jr, C. A. (2012). Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biological Psychiatry, 72(7), 555–561. (PubMed ID: 22521148)

Zarate Jr, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., … & Luckenbaugh, D. A. (2013). A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biological Psychiatry, 74(4), 257–264. (PubMed ID: 23206319)

Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., … & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681-688. (PubMed ID: 24740528)

Leave a Comment

Your email address will not be published. Required fields are marked *

More To Explore

Ketamine Clinic

New ICER Report Takes Hard Look at Spravato

The Institute for Clinical and Economic Review (ICER) released a statement on June 19th questioning the efficacy and cost effectiveness of treating resistant depression with esketamine (Spravato). The “report-at-a-glance”, linked *here*, summarizes the *full report*. ICER believes a reduction in price of 25-52% would be needed to improve cost-effectiveness. Spravato’s current list price of $32,400

Sunbelt Health

Sunbelt Joins TriWest Healthcare Alliance!

Everyone has a story that led them to this place; stories that they perceive to be written in ink. When asked about their story, longtime sufferers recite a mantra of pain and hardship ingrained in every aspect of their lives. As providers, we try to break these cycles by utilizing effective treatment regimens. Ketamine, in